Substituted nucleosides, nucleotides and analogs thereof

Patent metadata

Field	Value
Publication number	US-11773126-B2
Application number	US-202117446007-A
Country	US
Kind code	B2
Filing date	Aug 26, 2021
Priority date	Sep 18, 2017
Publication date	Oct 3, 2023
Grant date	Oct 3, 2023

Abstract

Disclosed herein are compounds of the Formula (I) and pharmaceutically acceptable salts thereof: (I) where the variables in Formula (I) are described herein. Methods of synthesizing such compounds and methods of using them to treat diseases and/or conditions such as a Picornaviridae, Flaviviridae, Filoviridae, Pneumoviridae and/or Coronaviridae viral infections are also disclosed.

First claim

What is claimed is:

1. A compound of Formula (Ia2), having the structure:

or a pharmaceutically acceptable salt thereof,
wherein:
R 4A is selected from the group consisting of: fluoro, cyano, azido and C 1-4 alkyl substituted with one or more substituents selected from fluoro and chloro;
R 5 A is

R 9A is

and
R 33A is C 1-6 alkyl.

2. The compound of claim 1 , wherein the compound of Formula (I) is

or a pharmaceutically acceptable salt thereof.

3. A pharmaceutical composition comprising an effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent, excipient, or combination thereof.

4. A method of ameliorating or treating a viral infection comprising administering an effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof, to a subject suffering from the viral infection, wherein the viral infection is a Picornaviridae, Flaviviridae, Filoviridae, Pneumoviridae, or Coronaviridae viral infection.

5. The method of claim 4 , wherein the Picornaviridae viral infection is a Rhinovirus infection; the Flaviviridae viral infection is a Dengue virus infection or a Hepacivirus infection; the Filoviridae viral infection is an Ebolavirus infection; the Pneumoviridae viral infection is a human respiratory syncytial virus (HRSV) infection; the Pneumoviridae viral infection is a human respiratory syncytial virus (HRSV) infection; and the Coronaviridae viral infection is a human a-coronavirus viral infection or a human β-coronavirus viral infection.

6. The method of claim 4 , wherein the viral infection is a Coronaviridae viral infection.

7. The method of claim 6 , wherein the Coronaviridae viral infection is a human α-coronavirus viral infection or human β-coronavirus viral infection.

8. The method of claim 4 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

Assignees

• Janssen Pharmaceuticals Inc

Inventors

• Beigelman Leonid
• Deval Jerome
• Prhavc Marija

Classifications

• C07H7/06 Primary

  Heterocyclic radicals · CPC title

• A61P31/14

  for RNA viruses · CPC title

• A61P31/16

  for influenza or rhinoviruses · CPC title

• C07H9/04

  Cyclic acetals · CPC title

• C07H19/23 Primary

  Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22 · CPC title